^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HR positive

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    2099; 5241
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    17h
    A Prospective, Cohort, Open Study of Immunoradiotherapy Combined with Cidarbenamide and PD-1 Monotherapy in the Backline Treatment of Advanced Solid Tumors (ChiCTR2300068737)
    P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67
    Enrollment open • Phase classification • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    18h
    ATOM-1st: Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment (clinicaltrials.gov)
    P=N/A, N=1235, Not yet recruiting, Chirec
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • irinotecan
    1d
    Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. (PubMed, Cancer Med)
    Patients with HR+/HER2- ABC receiving palbociclib with higher comorbidity burden, especially blood and lymphatic system disorders, had poorer clinical outcomes. GHS/QoL was preserved regardless of comorbidity burden.
    Clinical data • Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Ibrance (palbociclib)
    1d
    Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. (PubMed, Breast Cancer (Dove Med Press))
    Capecitabine and paclitaxel demonstrated comparable efficacy after CDK4/6i progression, with no significant differences in PFS or OS. Given their distinct toxicity profiles, treatment selection should be individualized according to patient characteristics and tolerability.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    paclitaxel • capecitabine
    1d
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR positive • HER-2 negative • ESR1 mutation • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
    |
    Guardant360® CDx
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    2d
    AMBITION: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    2d
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine
    2d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group | N=1050 --> 1520
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • Orserdu (elacestrant)
    2d
    A Rare Case of Palbociclib-Induced Pancolitis: Clinical Insights and Literature Review. (PubMed, Cureus)
    While generally well tolerated, their toxicity profiles differ, with palbociclib and ribociclib more commonly associated with hematologic toxicity and abemaciclib with gastrointestinal adverse effects such as diarrhea...We report a 65-year-old woman with metastatic HR+ breast cancer who presented with a two-week history of watery diarrhea (10-12 episodes/day), abdominal cramping, and a 5-pound weight loss while receiving palbociclib, fulvestrant, and denosumab...Although biopsy later demonstrated cytomegalovirus (CMV) positivity, antiviral therapy was deferred given negative CMV PCR and complete clinical resolution. This case highlights an uncommon presentation of palbociclib-induced pancolitis and underscores the importance of careful clinical evaluation and contextual interpretation of histologic findings to avoid unnecessary treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Prolia (denosumab)
    3d
    Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=44, Recruiting, Centro di Riferimento Oncologico - Aviano
    New trial
    |
    HR positive
    3d
    2025-370: A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=92, Recruiting, Henan Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi)
    3d
    Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKang (dalpiciclib)